In vitro susceptibility of Cryptococcus gattii clinical isolates

Authors: Gomez-Lopez, A.¹; Zaragoza, O.¹; Dos Anjos Martins, M.²; Melhem, M. C.²; Rodriguez-Tudela, J. L.¹; Cuenca-Estrella, M.¹

Source: Clinical Microbiology & Infection, Volume 14, Number 7, July 2008 , pp. 727-730(4)

Publisher: Wiley-Blackwell

Buy & download fulltext article:

You have access to the full text article on a website external to ingentaconnect.

Please click here to view this article on Wiley Online Library.

You may be required to register and activate access on Wiley Online Library before you can obtain the full text. If you have any queries please visit Wiley Online Library

Abstract:

The data available in the literature concerning Cryptococcus gattii in vitro antifungal susceptibility are contradictory. We have analyzed the activity of eight antifungal agents against 23 C. gattii clinical isolates and compared the susceptibility profiles with those of C. neoformans. MIC analysis (mg/L) revealed that C. gattii isolates were more susceptible to amphotericin B and flucytosine than were C. neoformans isolates. Fluconazole and other azole compounds showed high MIC values for C. gattii. Posaconazole displayed good activity. Further studies are required to ascertain the predictive value of the in vitro data presented here.

Keywords: Antifungal susceptibility testing; Cryptococcus gattii; emerging yeast; EUCAST method; posaconazole

Document Type: Research article

DOI: http://dx.doi.org/10.1111/j.1469-0691.2008.02021.x

Affiliations: 1: Servicio de Micología, Centro Nacional de Microbiología, Instituto de Salud Carlos III, Majadahonda (Madrid), Spain 2: SeÇao de Micología, ServiÇo de Parasitología, Instituto Adolfo Lutz, Sao Paulo, Brasil

Publication date: 2008-07-01